Olga Vitek

Dr. Vitek holds a PhD in Statistics from Purdue University. She is currently Professor in the Khoury College of Computer Sciences, and affiliated faculty in the Department of Chemistry and Chemical Biology at Northeastern University. Her research intersects statistical science, machine learning, mass spectrometry, proteomics and systems biology. Statistical methods and open-source software MSstats and Cardinal developed in her lab are widely used in academia and industry. Dr. Vitek is an elected Fellow of the American Statistical Association, a recipient of the Gilbert S. Omenn Computational Proteomics Award of the US Human Proteome Organization (HUPO). She is also a recipient of the CAREER award of the National Science Foundation, and of the Essential Open-source Software Award of the Chan-Zuckerberg foundation. She is Associate Editor of the journal Bioinformatics.

Devon Kohler

Devon Kohler is a PhD student at Northeastern University’s Khoury College of Computer Science in Dr. Olga Vitek’s lab. Prior to starting his PhD he received a Master’s of Science in Data Science from Northeastern. His research interests are in the application of statistical and causal inference to biological experiments, mainly proteomics and systems biology. He is the main author of a variety of statistical methods for the analysis of mass spectrometry-based proteomics, including MSstatsPTM, MSstatsLiP, and MSstatsShiny.

Alexey Nesvizhskii

Alexey Nesvizhskii is endowed Godfrey Dorr Stobbe Professor of Bioinformatics in the Departments of Pathology and Computational Medicine & Bioinformatics, University of Michigan Medical School, Ann Arbor. Prior to joining the University of Michigan in 2005, Dr. Nesvizhskii received Ph.D. in Physics from the University of Washington and completed post-doctoral research training in Ruedi Aebersold lab at the Institute for Systems Biology in Seattle. His research laboratory is working in the areas of mass spectrometry-based proteomics and proteogenomics, bioinformatics, and multi-omics data integration. The computational methods and tools developed by Dr. Nesvizhskii and his colleagues, such as PeptideProphet and ProteinProphet (the Trans-Proteomic Pipeline), SAINT, CRAPome, DIA-Umpire, FragPipe (MSFragger, Philosopher, IonQuant) are among the most cited proteome bioinformatics tools and are used by thousands of laboratories worldwide. He has published over 200 manuscripts in international scientific journals. His lab actively collaborates with technology developers, biologists, and clinical scientist. Dr. Nesvizhskii served as Senior Editor for international journals Proteomics and Proteomics-Clinical Applications, as Section Editor in the areas of proteomics for BMC Bioinformatics, and on the Editorial Board of Molecular and Cellular Proteomics. He is a member of the Scientific Advisory Board for Swiss Institute of Bioinformatics, and he also currently serves a three-year term on the Council of the Human Proteome Organization (HUPO). At the University of Michigan, Dr. Nesvizhskii directs the NCI-funded T32 Proteogenomics of Cancer Training Program. He also directs the Proteomics Resource Facility which provides cutting-edge proteomics capabilities to UM investigators.

Fengchao Yu

Fengchao is a research investigator from the Alexey Nesvizhskii Lab at the University of Michigan. His research interests include peptide identification, PTM discovery, label-free quantification, isotopic-labeling quantification, isobaric-labeling quantification, and DIA data analysis. Currently, Fengchao is the leading developer of FragPipe, MSFragger, and IonQuant. These tools have been used by research laboratories and companies in the United States and worldwide. He has also published papers in journals such as Nature Methods, Nature Biotechnology, Nature Communications, Molecular & Cellular Proteomics, and Journal of Proteome Research.

Peggi Angel

Coming Soon!

Stephanie Cologna

Coming Soon!

Kevin Schey

Coming Soon!

Jennifer Van Eyk

Dr. Van Eyk is a Professor of Medicine at Cedars-Sinai Medical Center, Director of the Basic Science Research in the Barbra Streisand Woman’s Hearth Center and Director of the new Advance Clinical Biosystems Institute where she recently moved from Johns Hopkins University. Most recently she has become the co-director of the Cedars Sinai Precision Health, focused on in-hospital and population individualization of health care. Dr. Van Eyk is an international leader in the area of clinical proteomics and her lab has focused the developing technical pipelines for de novo discovery and larger scale quantitative mass spectrometry methods. This includes multiple reaction monitoring (MRM, also known as SRM) and most recently data independent acquisition. Her laboratory is well known for the extreme technical quality of the data generated, rigorous quality control with tight %CV while applying these to key clinical questions. The aim is to maximize throughput and reproducibility in order to move targeted and robust discovery methods into large population healthy continuous assessment and clinical grade assays focusing on brain and cardiovascular diseases.

John Yates

Coming Soon!

Yeoun Jin Kim

Coming Soon!

Hanno Steen

Coming Soon!

Wei-Jun Qian

Coming Soon!

Annie Moradian

Coming Soon!

Nathalie Agar

Coming Soon!

Olga Vitek

Dr. Vitek holds a PhD in Statistics from Purdue University. She is currently Professor in the Khoury College of Computer Sciences, and affiliated faculty in the Department of Chemistry and Chemical Biology at Northeastern University. Her research intersects statistical science, machine learning, mass spectrometry, proteomics and systems biology. Statistical methods and open-source software MSstats and Cardinal developed in her lab are widely used in academia and industry. Dr. Vitek is an elected Fellow of the American Statistical Association, a recipient of the Gilbert S. Omenn Computational Proteomics Award of the US Human Proteome Organization (HUPO). She is also a recipient of the CAREER award of the National Science Foundation, and of the Essential Open-source Software Award of the Chan-Zuckerberg foundation. She is Associate Editor of the journal Bioinformatics.

Fengchao Yu

Fengchao is a research investigator from the Alexey Nesvizhskii Lab at the University of Michigan. His research interests include peptide identification, PTM discovery, label-free quantification, isotopic-labeling quantification, isobaric-labeling quantification, and DIA data analysis. Currently, Fengchao is the leading developer of FragPipe, MSFragger, and IonQuant. These tools have been used by research laboratories and companies in the United States and worldwide. He has also published papers in journals such as Nature Methods, Nature Biotechnology, Nature Communications, Molecular & Cellular Proteomics, and Journal of Proteome Research.

Devon Kohler

Devon Kohler is a PhD student at Northeastern University’s Khoury College of Computer Science in Dr. Olga Vitek’s lab. Prior to starting his PhD he received a Master’s of Science in Data Science from Northeastern. His research interests are in the application of statistical and causal inference to biological experiments, mainly proteomics and systems biology. He is the main author of a variety of statistical methods for the analysis of mass spectrometry-based proteomics, including MSstatsPTM, MSstatsLiP, and MSstatsShiny.

Alexey Nesvizhskii

Alexey Nesvizhskii is endowed Godfrey Dorr Stobbe Professor of Bioinformatics in the Departments of Pathology and Computational Medicine & Bioinformatics, University of Michigan Medical School, Ann Arbor. Prior to joining the University of Michigan in 2005, Dr. Nesvizhskii received Ph.D. in Physics from the University of Washington and completed post-doctoral research training in Ruedi Aebersold lab at the Institute for Systems Biology in Seattle. His research laboratory is working in the areas of mass spectrometry-based proteomics and proteogenomics, bioinformatics, and multi-omics data integration. The computational methods and tools developed by Dr. Nesvizhskii and his colleagues, such as PeptideProphet and ProteinProphet (the Trans-Proteomic Pipeline), SAINT, CRAPome, DIA-Umpire, FragPipe (MSFragger, Philosopher, IonQuant) are among the most cited proteome bioinformatics tools and are used by thousands of laboratories worldwide. He has published over 200 manuscripts in international scientific journals. His lab actively collaborates with technology developers, biologists, and clinical scientist. Dr. Nesvizhskii served as Senior Editor for international journals Proteomics and Proteomics-Clinical Applications, as Section Editor in the areas of proteomics for BMC Bioinformatics, and on the Editorial Board of Molecular and Cellular Proteomics. He is a member of the Scientific Advisory Board for Swiss Institute of Bioinformatics, and he also currently serves a three-year term on the Council of the Human Proteome Organization (HUPO). At the University of Michigan, Dr. Nesvizhskii directs the NCI-funded T32 Proteogenomics of Cancer Training Program. He also directs the Proteomics Resource Facility which provides cutting-edge proteomics capabilities to UM investigators.

Ben Orsburn

Coming Soon!

Jarrod Sandow

Coming Soon!

Jessica Nickerson

Coming Soon!

Yonghao Yu

Dr. Yu received his B.S. in Chemistry from Fudan University (Shanghai, China) in 2001, and then his Ph.D. in Chemistry from the University of California, Berkeley in 2006. His doctoral research with Dr. Julie Leary focused on mass spectrometry-based proteomic technologies and chemical biology of novel protein modifications. Dr. Yu completed his postdoctoral training (2007-2011) with Drs. Steven Gygi and John Blenis in the Department of Cell Biology at Harvard Medical School. During his postdoctoral training, Dr. Yu studied the function and regulation of phosphorylation-dependent signaling mechanisms in cell growth control. Dr. Yu began his independent research career in 2012 in the Department of Biochemistry at the University of Texas Southwestern Medical Center, where he was a CPRIT scholar in cancer research and a Virginia Murchison Linthicum Scholar in Medical Research. He was promoted to Associate Professor with tenure in 2017. In 2022, Dr. Yu was recruited to join the Department of Molecular Pharmacology and Therapeutics at Columbia University Irving Medical Center as a full professor. Using a multidisciplinary approach, his lab has contributed significantly to our molecular understanding of novel covalent protein modifications in the human proteome. Dr. Yu is also particularly interested in translating the mechanistic insights into novel therapeutic strategies for the relevant diseases, including cancer, diabetes, and neurodegeneration. Through the years, Dr. Yu has been involved in many teaching and scientific outreach activities. He has also served on many NIH and DoD advisory panels, including as a current member of the NIH Enabling Bioanalytical and Imaging Technologies (EBIT) Study Section.

Yue Chen

Yue Chen is an Associate Professor in Biochemistry at the University of Minnesota, Twin Cities. He conducted graduate studies in biochemistry under the guidance of Dr. Yingming Zhao at UT Southwestern Medical Center and received Ph.D. in 2009. Upon graduation, he continued postdoctoral research with Dr. Zhao at the University of Chicago with a primary focus on the discovery and quantification of novel lysine short-chain acylations that are involved in cell metabolism and epigenetics. He joined the Department of Biochemistry, Molecular Biology and Biophysics at the University of Minnesota, Twin Cities in 2013. His lab develops innovative quantitative proteomics and bioinformatics strategies for functional proteomics analysis of protein posttranslational modification pathways involved in protein homeostasis and metabolic signaling. He has published over 70 research papers and book chapters. He was the recipient of NIH MIRA award and NSF CAREER award.

David Roberts

I am currently a chemistry Ph.D. candidate at the University of Wisconsin-Madison under the joint mentorship of Professors Ying Ge and Song Jin, where I am supported by an American Heart Association (AHA) predoctoral fellowship. My doctoral work has focused on establishing new intact protein, “top-down”, mass spectrometry (MS) compatible methodologies and functionalized nanomaterials that can be utilized to investigate a wide range of chemical and biological questions. Focusing on addressing the major challenges of the human proteome dynamic range and the analysis of complex proteins with post-translational modifications (PTMs), my highly interdisciplinary doctoral work ultimately has focused on providing new technologies and methods for investigating glycoproteins, cardiovascular related proteins, receptor membrane proteins, and, by extension, the human proteome. I have published multiple first authored and co-first authored papers in Nature Comm, Nano Res, Anal Chem, Part. Part. Syst. Charact., JASMS, as well as two co-corresponding authorship papers in JACS and Chem Sci. My long-term career goal is to bridge the diverse silos of nanotechnology and MS-based proteomics to become a professor at a well-established research institution, and to lead a multidisciplinary research team focused on developing innovative chemical methods and technologies to address significant problems in biology and human health.

Ronghu Wu

Dr. Ronghu Wu is an associate professor in the School of Chemistry and Biochemistry at Georgia Institute of Technology. His group has worked on the development of mass spectrometry-based methods for global analysis of protein modifications, especially glycosylation, and applying them for biomedical research. Glycosylation is one of the most common and important protein modifications in mammalian cells, and it regulates nearly every extracellular activity. Aberrant protein glycosylation is directly related to multiple human diseases including cancer and infectious diseases. Global analysis of protein glycosylation will advance our understanding of glycoprotein functions and disease mechanisms, leading to the identification of glycoproteins as effective biomarkers and drug targets. However, it is very challenging to globally analyze glycoproteins in complex biological samples because of the heterogeneity of glycans and the low abundance of many glycoproteins. It is urgently needed to develop effective methods to comprehensively characterize protein glycosylation. He is a recipient of Georgia Tech (GT) Blanchard Assistant Professorship (2014), NSF CAREER Award (2015), American Society for Mass Spectrometry Research Award (2016), GT College of Sciences Cullen-Peck Faculty Scholar Award (2019), and GT Vasser-Woolley Professorship in 2021.

Daniel Polasky

Daniel A. Polasky is a Research Investigator in the lab of Prof. Alexey Nesvizhskii in the department of Pathology at the University of Michigan. His research focuses on developing computational tools and methods for proteomics, with a particular focus on glycosylation and other post-translational modifications. He is a member of the MSFragger and FragPipe development teams, including leading work on MSFragger Glyco and associated tools for glycoproteomics data analysis. Before moving into computational proteomics, his PhD work in the lab of Prof. Brandon Ruotolo focused on developing mass spectrometry and ion mobility-mass spectrometry methods for analysis of intact proteins and protein complexes.

Yixuan (Axe) Xie

Yixuan (Axe) Xie, Ph.D., is a postdoctoral research associate in the laboratory of Dr. Benjamin Garcia, where he is focusing on developing MS-based methods to characterize protein and RNA modifications for understanding their biological roles. He obtained his Ph.D. at the University of California, Davis, under the mentorship of Dr. Carlito Lebrilla. During his Ph.D., he established bioorthogonal tools to investigate the glycan-mediated interactions on the cell surface, as well as glycoproteomic and glycomic methods to monitor the cell glycosylation state during significant biological events.

Birgit Schilling

Dr. Schilling is an Associate Professor and the Director of the Mass Spectrometry Core at the Buck Institute for Research on Aging in California, and she is also an Adjunct Professor at the University of Southern California (USC). The Schilling lab develops and implements advanced innovative protein analytical technologies (including quantitative proteomics, posttranslational modifications, protein dynamics and biomarker discovery) to advance basic biology and biomedical research related to aging research. Several research projects include investigation of protein phosphorylation, acylation, and other posttranslational modifications, as well as differential expression of proteins during disease and aging processes. We are particularly interested in deciphering underlying mechanisms of senescence during aging, and we have developed MS methodologies to quantitatively analyze protein secretomes, secreted exosomes and to perform accurate quantitative protein expression workflows. The Schilling lab has adopted several novel proteomic technologies with comprehensive and extremely sensitive quantification capabilities, and these are particularly applicable for the proposed project. We are using proteomic data-independent acquisitions (DIA), or SWATH which allows us to accurately determine changes in relative protein expression level between multiple different conditions.

Brett Phinney

Coming Soon!

Jordan Burton

Jordan B. Burton is a postdoctoral research scientist in the Schilling Lab at the Buck Institute for Research on Aging. Dr. Burton studied Chemistry at Lake Superior State University and received his Doctorate (PhD) from Wayne State University in Detroit, Michigan. Jordan joined the Schilling lab in February 2022 to pursue his passion for large -omic analytical technologies. In the short time he has been at the Buck institute he has already taken on two high profile projects, one of which is a human cancer study aimed at discriminating the proteomes of different breast cancer subtypes. Jordan contributes to the Schilling lab with his expertise in the acquisition and analysis of large datasets using mass spectrometry to efficiently determine changes in protein expression in biological samples. Jordan has an excellent understanding of bottom-up proteomics, label-free data-independent acquisitions, and more recently also worked on highly translational scientific projects, such as analyzing a large human breast cancer cohort, a large human brain aging cohort, and also acute kidney injury models testing therapeutic interventions. He is also interested in developing new ideas for novel and unique data visualization and communication, that enable non-MS-experts and biological collaborators to appreciate meaningful differences between study groups.

Benjamin Garcia

Benjamin A. Garcia obtained his BS in Chemistry at UC Davis in 2000, where he worked as an undergraduate researcher in Prof. Carlito Lebrilla’s laboratory. He received his PhD in Chemistry in 2005 at the University of Virginia under Prof. Donald Hunt and then was an NIH NRSA Postdoctoral Fellow at the University of Illinois under Prof. Neil Kelleher from 2005-2008. From there Ben was appointed as an Assistant Professor in the Molecular Biology Department at Princeton University from 2008-2012, until his recruitment as the Presidential Associate Professor of Biochemistry and Biophysics at the University of Pennsylvania Perelman School of Medicine in 2012, promoted to full Professor in 2016, and named the John McCrea Dickson M.D. Presidential Professor in 2017. Ben moved in the summer of 2021 to the Washington University School of Medicine in St. Louis to become the Raymond H. Wittcoff Distinguished Professor and Head of the Department of Biochemistry and Molecular Biophysics. The Garcia lab has been developing and applying novel proteomic approaches and bioinformatics for interrogating protein modifications, especially those involved in epigenetic mechanisms such as histones during human disease, publishing over 385 publications. He is presently an Associate Editor of the Analytical Chemistry, and Mass Spectrometry Reviews journals; and serves on the editorial boards for the Molecular Omics, the Journal of Proteome Research and the Molecular and Cellular Proteomics journals. He also serves on the Board of Directors for the U.S. Human Proteome Organization (HUPO), the HUPO Governing Council/Executive Committee and the Executive Committee of the American Chemical Society (ACS) Analytical Chemistry Division. Ben has been recognized with many honors and awards for his mass spectrometry research including the American Society for Mass Spectrometry (ASMS) Research Award, a National Science Foundation CAREER award, an NIH Director’s New Innovator Award, the Presidential Early Career Award for Scientists and Engineers (PECASE), an Alfred P. Sloan Fellowship, the PITTCON Achievement Award, the Ken Standing Award, the ACS Arthur F. Findeis Award, The Protein Society Young Investigator Award, the ASMS Biemann Medal, the HUPO Discovery in Proteomic Sciences Award, and was named a Fellow of the Royal Society of Chemistry.

Ben Orsburn

Ben is a newly independent investigator at the Johns Hopkins University Medical School where he collaborates frantically in an attempt to solve weird problems with mass spectrometry.

Brett Phinney

Coming Soon!

Benjamin Neely

Coming Soon!

Milan Mrksich

Milan Mrksich is the Vice President for Research at Northwestern University, where he is also the Henry Wade Rogers Professor with appointments in the Departments of Biomedical Engineering, Chemistry, and Cell and Developmental Biology. He was the Founding Director of the Center for Synthetic Biology and served as Associate Director of the Robert H. Lurie Comprehensive Cancer Center. He earned a BS degree in Chemistry from the University of Illinois and a PhD in Chemistry from Caltech. He then served as an American Cancer Society Postdoctoral Fellow at Harvard University before joining the Chemistry faculty at the University of Chicago in 1996, where he remained until his move to Northwestern in 2011. His honors include the Camille Dreyfus Teacher-Scholar Award, the TR100 Innovator Award, the Arthur C. Cope Scholar Award, the Illinois Bio ICON Innovator Award, the Pittsburgh Analytical Chemistry Award, and election to the American Institute for Medical and Biological Engineering. Dr. Mrksich is a leader in the science and engineering of materials that contact biological environments. His laboratory has pioneered several technologies, including strategies to integrate living cells with microelectronic devices, methods to enable high throughput assays for drug discovery, and approaches to making synthetic proteins for therapeutic applications. Most notably, he developed the SAMDI biochip technology that allows enzymes to be tested at a rate of a hundred thousand per day, and that has become the leading ‘label-free’ technology in drug discovery. His work has been described in approximately 225 publications and 750 invited talks. Professor Mrksich is an active advisor in government and industry. His present and past appointments include the Microsystems Exploratory Council, the Chair of the Defense Sciences Research Council—both advisory groups to the Defense Department—the Board of Governors for Argonne National Laboratory, Board of Directors for the Camille & Henry Dreyfus Foundation, and the Scientific Director of the Searle Scholars Program. He has also been active as an entrepreneur. He is Founder of SAMDI Tech, an Illinois-based contract research organization that has commercialized his high throughput assays for discovering drug leads and that now serves global pharmaceutical companies. He is also a co-Founder of Lyra Therapeutics (NASDAQ: LYRA), a company that has developed stents for the treatment of small vessels in ear, throat and nose diseases and recently founded ModuMab Therapeutics, which is developing next-generation immunotherapies. He has also served on a dozen Scientific Advisory Boards of other life sciences startup companies.

Nicolai Bache

Coming Soon!

Christoph Borchers

Coming Soon!

Saeed Seyedmohammad

Coming Soon!

Debadeep BHATTACHARYYA

Coming Soon!

David Muddiman

David C. Muddiman is the Jacob and Betty Belin Distinguished Professor of Chemistry and Director, Molecular Education, Technology and Research Innovation Center (METRIC) at North Carolina State University in Raleigh, NC. Prior to moving his research group to North Carolina State University in 2005, David was a Professor of Biochemistry and Molecular Biology and Founder and Director of the Proteomics Research Center at the Mayo Clinic College of Medicine in Rochester, MN. Prior to this appointment, David was an Associate Professor of Chemistry at Virginia Commonwealth University. It was there that he began his professional career as an assistant professor with an adjunct appointment in the Department of Biochemistry and Molecular Biophysics and as a member of the Massey Cancer Center in 1997. These academic appointments were preceded by a postdoctoral fellowship at Pacific Northwest National Laboratory in the Environmental Molecular Sciences Laboratory under Richard D. Smith from 1995-1997. David was born in Long Beach, CA in 1967 but spent most of his formative years in a small town in Pennsylvania. David received his B.S. in chemistry from Gannon University (Erie, PA) in 1990 and his Ph.D. in Analytical Chemistry from the University of Pittsburgh in 1995 under the auspices of David M. Hercules. Dr. Muddiman was Editor of Analytical and Biological Chemistry (2015-2020) and he currently the Coordinating Editor of Journal of Mass Spectrometry (2022-present) serves on the Editorial Advisory Board of Molecular and Cellular Proteomics, Rapid Communications in Mass Spectrometry, and the Journal of Chromatography B. He also serves as the Chair of the advisory board of the NIH Funded Yale/NIDA Neuroproteomics Center, Yale University. Dr. Muddiman has served as a member of the ASMS Board of Directors (2013-2015) and Treasurer (2013-2015) and President (2015-2017) of the United States Human Proteome Organization. His group has presented over 700 invited lectures and presentations at national and international meetings including 32 plenary/keynote lectures. His group has published over 300 peer-reviewed papers and has received six US patents. He is the recipient of the 2016 Graduate School Outstanding Graduate Faculty Mentor Award in the Mathematical, Physical Sciences, and Engineering, 2015 ACS Award in Chemical Instrumentation, 2010 Biemann Medal (American Society for Mass Spectrometry), 2009 NCSU Alumni Outstanding Research Award, the 2004 ACS Arthur F. Findeis Award, the 1999 American Society for Mass Spectrometry Research Award, and the 1990-1991 Safford Award for Excellence in Teaching (University of Pittsburgh). Dr. Muddiman’s research is at the intersection of innovative mass spectrometry platform technologies, systems biology, environmental science, and model organisms to understand human disease and is largely funded by the National Institutes of Health.

Jeff Spraggins

The primary focus of my research program is the development of next-generation imaging mass spectrometry (IMS) technologies to elucidate the molecular basis of health and disease. Modern instrumentation and computing capabilities have enabled researchers to move beyond reductionist biology and, instead, probe how the components of biological entities (e.g. molecules, cells, and tissues) interact to reveal the underlying biology of disease. This systems biology approach has been accelerated by advancements in high-throughput ‘omics’ technologies, however, genetic and molecular information are only part of the story. The challenge lies in understanding how these parts interact and how perturbations to the system relate to disease. Molecular imaging effectively offers a ‘blueprint’ as to how biological components work together by providing spatial context to molecular information. From the advent of the complex microscope in the late 1600s to modern modalities such as magnetic resonance, positron emission tomography, and advanced microscopy, imaging technologies have always been at the forefront of our understanding of biochemistry and biology. However, relative to the new -omics technologies, these classical biomedical imaging technologies have limited molecular specificity. Mass spectrometry-based imaging now finds itself uniquely positioned to bridge the gap between the information rich genomics, proteomics, and metabolomics approaches and biomedical imaging technologies. IMS combines the molecular specificity of mass spectrometry with the spatial fidelity of classical histology to create molecular maps of tissues. Broadly, my research falls into two categories: (1) Developing novel mass spectrometry technologies to maximize imaging performance enabling molecular histology at cellular resolution and (2) combining imaging mass spectrometry with a variety of other biomedical imaging technologies to create new integrated modalities capable of providing a systems biology view of tissue at cellular resolution. We are applying these advanced technologies to better understand critical biomedical research areas such as infectious disease and diabetes.

Jorg Hanrieder

Dr Hanrieder has a background in chemistry from Leipzig Univ (MSc), Germany and a PhD from Uppsala University, Sweden specializing in chemistry and neuroscience. Following a postdoc within chemical imaging (Andrew Ewing, Chalmers University, Sweden) he started his own lab in 2015 as Assistant Professor in Neurochemistry at the University of Gothenburg Medical School. He was promoted to Associate Professor in 2017. In parallel he is leading a group at the Queen Square Institute of Neurology, University College London. His research involves the development and advancement of correlative biochemical imaging strategies to understand pathogenic protein aggregation processes underlying the pathology of many neurodegenerative diseases with particular focus on Alzheimers disease

Alison Scott

Coming Soon!

Manxi Yang

Coming Soon!

Rafael Melani

Dr. Rafael D. Melani is a Research Assistant Professor in Chemistry at Northwestern University (Evanston, US) and the Associate Director of the Proteomics Center of Excellence (PCE). He earned his BS degree in Biology (2010) and a master's degree from the University of Brasilia (Brasilia, Brazil). Under Dr. Gilberto Domont's supervision, he got his Ph.D. in Biochemistry (2016) from the Federal University of Rio de Janeiro - UFRJ (Rio de Janeiro, Brazil). Rafael's postdoctoral research (2016-2017) was performed in the Proteomics Unit at UFRJ. In 2017, he joined the Kelleher Research Group and the PCE at Northwestern University. Dr. Melani has extensive experience and training in top-down and bottom-up proteomics, venomics, protein fractionation, mass spectrometry, and native mass spectrometry. His research focuses on improving mass spectrometry-based solutions for the characterization of intact proteoforms in denatured and native conditions and developing translational top-down proteomics methods centered on proteoforms.

Ying Ge

Dr. Ying Ge is currently a Professor in the Department of Cell and Regenerative Biology and Department of Chemistry and Director of the Human Proteomics Program at the UW-Madison. She earned a B.S. in Chemistry from Peking University; Ph.D. from Cornell University under the joint supervision of Professors Fred McLafferty and Tadhg Begley. After graduate school, Dr. Ge explored a career in pharmaceutical industry. In 2012, Dr. Ge started her tenure-track Assistant Professor position, received tenure in 2015, and was promoted to Full Professor in 2019. Dr. Ge’s research is highly interdisciplinary that cuts across the traditional boundaries of chemistry, biology, and medicine. Dr. Ge has devoted her past twenty years in developing and applying top-down mass spectrometry-based proteomics to biomedical research. Recently her lab has developed a multi-pronged approach to address the challenges in top-down proteomics. By creatively integrating her expertise in mass spectrometry with cardiac biology, she has made significant contributions to understanding cardiac disease and regeneration. Dr. Ge has published over 150 papers with many in high impact journals and has been awarded three NIH R01 grants and a high-end instrument grant. She has received a number of awards including the ASMS Biemann Medal (2020), HUPO Clinical and Translational Proteomics Sciences Award (2021), and HPLC Society Georges Guiochon Faculty Fellowship (2016), as well as The Top 100 Analytical Scientist Power List (on a global scale, 2019, 2021) and The Top 10 Analytical Scientist Power List (in North America, 2020).

Kevin Zemaitas

Coming Soon!

Greg Kapp

Coming Soon!

Michael Major

Coming Soon!

Judith Steen

Coming Soon!

Parag Mallick

Coming Soon!

Ling Hao

Dr. Ling Hao is an Assistant Professor of Chemistry at the George Washington University. She received her PhD from the University of Wisconsin-Madison in Dr. Lingjun Li’s group and completed her postdoctoral training at the National Institutes of Health/National Institute of Neurological Disorders and Stroke (NIH/NINDS) in Dr. Richard Youle’s group and Dr. Michael Ward’s group. Since starting her independent career in 2019, She has received a Ralph E Powe Junior Faculty Enhancement Award from Oak Ridge Associated Universities, an NIH R01 grant, and GW UFF and CDRF grants to support her research in developing novel proteomic methods to study lysosomal and mitochondrial dysfunctions underlying brain diseases. Her group uses human stem cell-derived neuron models in combination with mass spectrometry, cell biology, and bioinformatic strategies to study organelle dynamics and disease mechanisms. She has been recognized as an Emerging Investigator by the Journal of American Society for Mass Spectrometry in 2021, a Young Investigator Award by the Chinese American Society for Mass Spectrometry, and a Rising Star Award by the Human Proteome Organization World Congress in 2022.

Judith Steen

Dr. Steen is an Associate Professor of Neurobiology at Harvard Medical School, a member of the Harvard Stem Cell Institute and the Director of the Neuroproteomics Laboratory in the F. M. Kirby Neuroscience Center at Boston Children’s Hospital. Her laboratory works to understand neuro-regeneration and neurodegenerative diseases using systems biology approaches. The laboratory develops novel qualitative and quantitative methodologies at the interface of proteomics and transcriptomics with special emphasis on computational proteomics approaches. These novel quantitative methods and bioinformatics tools developed by the Steen Laboratory are being applied to understand the biology of regeneration and neurodegeneration in both mouse models, stem cells and human tissues, to find molecular targets for therapeutics, and to identify biomarkers of the neurodegenerative process. Further functional studies using biochemical, molecular and cell biology approaches are used to verify and understand the role of the targets and biomarkers in the context of injury and disease. The goal of this research is to use molecular information provided by our quantitative proteomics measurements in order to ameliorate neurodegeneration and promote regeneration.is an Associate Professor of Neurobiology at Harvard Medical School, a member of the Harvard Stem Cell Institute and the Director of the Neuroproteomics Laboratory in the F. M. Kirby Neuroscience Center at Boston Children’s Hospital. Her laboratory works to understand neuro-regeneration and neurodegenerative diseases using systems biology approaches. The laboratory develops novel qualitative and quantitative methodologies at the interface of proteomics and transcriptomics with special emphasis on computational proteomics approaches. These novel quantitative methods and bioinformatics tools developed by the Steen Laboratory are being applied to understand the biology of regeneration and neurodegeneration in both mouse models, stem cells and human tissues, to find molecular targets for therapeutics, and to identify biomarkers of the neurodegenerative process. Further functional studies using biochemical, molecular and cell biology approaches are used to verify and understand the role of the targets and biomarkers in the context of injury and disease. The goal of this research is to use molecular information provided by our quantitative proteomics measurements in order to ameliorate neurodegeneration and promote regeneration.

Sandip Kumar Patel

Coming Soon!

Asim Siddiqui

Coming Soon!

Robin Park

Robin Park is a director of bioinformatics at Bruker Daltonics Life Science. With a computer science background, Robin Park has been in both industrial and academic proteomics research with 60 related publications. He had worked in one of the world’s leading proteomics laboratories as Director of Bioinformatics, the Yates Proteomics Group at Scripps Research for 16 years. In addition, Robin had been the CEO of Integrated Proteomics Applications, Inc. for 12 years, where Robin Park led a team to develop a commercial proteomics data analysis platform, a GPU search engine, and a prototype of a real-time search engine. After joining Bruker in 2020 as a director of bioinformatics, he has been focusing on research and innovation in bioinformatics.

Kylie Bemis

Kylie Bemis is faculty in the Khoury College of Computer Sciences at Northeastern University. She holds a B.S. degree in Statistics and Mathematics, a M.S. degree in Applied Statistics, and a Ph.D. in Statistics from Purdue University. In 2013, she interned at the Canary Center at Stanford for Cancer Early Detection, where she developed the Cardinal software package for statistical analysis of mass spectrometry imaging experiments. In 2015, she was awarded the John M. Chambers Statistical Software Award by the American Statistical Association for her work on Cardinal. In 2016, she joined the Olga Vitek lab for Statistical Methods for Studies of Biomolecular Systems at Northeastern University as a postdoctoral fellow. In 2019, she joined Northeastern as faculty, where she now teaches data science and develops curriculum for the MS in Data Science program. Her research interests include machine learning and large-scale statistical computing for bioinformatics. While at Purdue University, Kylie Bemis served as president of the Purdue chapter of the American Indian Science and Engineering Society (AISES) and secretary of the Native American Student Association (NASA). She is active in outreach to the Native American and LGBTQ communities. She is an enrolled member of the Zuni tribe, and she is a writer of fiction and poetry. Her short fiction has appeared in the anthologies Nameless Woman: An Anthology of Fiction by Trans Women of Color (2018), Maiden Mother Crone: Fantastical Trans Femmes (2019), and Transcendent 4: The Year’s Best Transgender Themed Speculative Fiction (2019).

Kevin Drew

Coming Soon!

Ella Doron-Mandel

Coming Soon!

Amanda Hummon

Amanda Hummon earned her AB in chemistry at Cornell University and her PhD in analytical chemistry at the University of Illinois, in the laboratory of Prof. Jonathan Sweedler. She completed her postdoctoral work at the National Cancer Institute. She is currently a Professor in the Department of Chemistry and Biochemistry and the Comprehensive Cancer Center at The Ohio State University. Her laboratory develops mass spectrometric methods to explore cancer tissues, cell cultures, and organoids

Hui Zhang

Hui Zhang graduated from Peking University with a BS and a MS degree and from University of Pennsylvania with a Ph.D. degree. After working at New England Biolabs, Cell Signaling Technology, and the Institute for Systems Biology, she joined Johns Hopkins University in 2006. Her research interests focus on using quantitative proteomics and proteogenomics to understand the regulations and functions of proteins and protein modifications.

Haiping Ouyang

Coming Soon!

Danqing Wang

Coming Soon!

Heather Desaire

Heather Desaire is the Dean’s Professor of Chemistry at the University of Kansas, where she has been on the faculty since 2002. She started her studies in Chemistry at Grinnell College, Grinnell, IA, where she earned a BA in 1997, and continued them at the University of California, Berkeley, where she earned her PhD in 2001. She spent a few months working in the pharmaceutical industry prior to starting her appointment at the University of Kansas. Her current research interests span the fields of mass spectrometry, machine learning, and glycobiology. She received a MIRA award from the National Institutes of Health to combine machine learning and omics analyses, and she has been recognized by the University of Kansas for excellence in teaching.

Brian Searle

Brian Searle is an Assistant Professor at the Ohio State University Medical Center in the Department of Biomedical Informatics and a member of the Pelotonia Institute for Immuno-Oncology (PIIO). Brian received his chemistry BA at Reed College in 2001. In 2004, he co-founded Proteome Software with Mark Turner and Dr. Ashley McCormack to produce and distribute cutting-edge data analysis software for proteomicists. In 2014, he returned to academia to earn his PhD with Dr. Michael MacCoss at University of Washington, where he developed methods to detect and quantify proteins and phosphosites using mass spectrometry. His lab at PIIO spans the intersection of proteomics, mass spectrometry, bioinformatics, and technology development to study human genetic variation in the backdrop of cancer.

Wen Jiang

Coming Soon!

Fengchao Yu

Fengchao is a research investigator from the Alexey Nesvizhskii Lab at the University of Michigan. His research interests include peptide identification, PTM discovery, label-free quantification, isotopic-labeling quantification, isobaric-labeling quantification, and DIA data analysis. Currently, Fengchao is the leading developer of FragPipe, MSFragger, and IonQuant. These tools have been used by research laboratories and companies in the United States and worldwide. He has also published papers in journals such as Nature Methods, Nature Biotechnology, Nature Communications, Molecular & Cellular Proteomics, and Journal of Proteome Research.

Bobbie- Jo Webb-Robertson

Bobbie-Jo Webb-Robertson has 20 years of experience in the statistics and data science fields. She currently serves as the chief scientist of computational biology in the Biological Sciences Division at PNNL. Her research portfolio is largely related to the biomedical field and primarily focuses on the development and application of advanced statistical and machine learning methods to address challenges associated with large and complex omics data, as well as integration across multiple data sources. She is a highly accomplished publisher with an h-index of 30 and more than 100 publications.

Yilin Xu

Yilin Xu works as Senior Manager in Data Science and Analytics at AbbVie. Yilin has over 15 years of experience in cellular oncology and genomics applied to molecular drivers of human diseases. She is an experienced research scientist with extensive bioinformatic and data science skills. In her current role, Yilin is leading scientific analytics team working closely with scientists in precision medicine to develop bioinformatics pipeline, ML and advanced visualization platform to identify prognostic and predictive biomarkers for disease progression and drug response.

Liang Jin

Dr. Liang Jin is a Senior Scientist II in DMPK Department at AbbVie Bioresearch Center in Worcester, MA. Dr. Jin received his Ph.D. in Molecular and Cellular Biology from Stony Brook University. At AbbVie, Dr. Jin has been working on establishing and optimizing data analysis workflows for label-free proteomics, integrating multi-omics data for target and biomarker discovery, and acquiring biological understanding through deep data mining. Dr. Jin is currently the leading bioinformatician in the omics technology group.

Brett Engelmann

Brett Engelmann is a Data Scientist at AbbVie working to create, explore, and interactively visualize analysis results from high throughput biology (omic) experiments. His main interest is phosphoproteomic experimental design and analysis for target ID and validation, but he is currently working on the development of an open-source omic study visualization, archival and exploration tool called OmicNavigator.

Abhishek Pandey

Abhishek is group lead for Machine Learning team called RAIDERS: Pharma Discovery in abbvie. His team works in field of Machine Learning in chemistry and drug discovery, Machine Learning in imaging/multi-omics, genomics and Machine Learning in-charge of Abbvie-calico collaboration. He is a Principal Research Scientist in Machine Learning and Deep learning. In his previous life he was inaugural member of precision medicine AI team and helped build and transform Tempus Labs Inc.

Benoit Lahallier

Coming Soon!

Christopher Adams

Coming Soon!

Valdemaras Petrosius

Coming Soon!

Yansheng Liu

Yansheng Liu is an Assistant Professor in the Department of Pharmacology at Yale University School of Medicine. He is also a group leader in quantitative proteomics at the Yale Cancer Biology Institute and Yale Cancer Center. Dr. Liu received his Ph.D. in Biomedical Sciences from the Chinese Academy of Sciences in 2011. He then carried out his post-doctoral training at ETH Zurich, Switzerland, under the mentorship of Ruedi Aebersold. In December 2017, Yansheng joined the faculty at Yale and began his independent career. His research program is focused on analyzing protein turnover and post-translational modifications for understanding cancer aneuploidy, cellular signaling transduction, and biodiversity. The Liu Lab also aims to contribute to the development of multiplexed data-independent acquisition mass spectrometry (DIA-MS) approaches. To date, Dr. Liu has co-authored 65 research and review articles. He has received the 2019 ASMS Emerging Investigator, the 2021 ASMS Research Award, the 2021 HUPO ECR Award (winner), and the 2023 US HUPO Robert J. Cotter New Investigator Award. He serves as an editorial board member of Proteomics and Proteomics-Clinical Applications, a scientific advisory board member for Review Commons, and a member of the HUPO Awards Committee and HUPO ETC Committee.

Marko Jovanovic

Marko Jovanovic did his PhD in the lab of Michael Hengartner at the University of Zurich, Switzerland. In close collaboration with the Ruedi Aebersold lab at the ETH Zurich, they developed novel large-scale approaches to identify microRNA targets genes in C. elegans. After his PhD, he joined the group of Aviv Regev at the Broad Institute of MIT and Harvard in Cambridge, USA. In collaboration with the Steven Carr lab at the Broad Institute, they developed new methods to integrate transcriptomics and proteomics data in order to gain new insight about how protein level changes are regulated during the immune response of dendritic cells. Marko started his own research group at Columbia University in 2017. The overarching research goal of his lab is to understand the principles and mechanisms by which translational regulation controls the dynamics of gene expression and therefore affects processes like differentiation, stress response and pathogenesis.

Xian Chen

Dr. Xian Chen is a Professor in the Dept. of Biochemistry and Biophysics, School of Medicine at University of North Carolina (UNC)-Chapel Hill. He is also the Director of Technology Development at UNC Proteomic Center. Dr Chen has multi-disciplinary expertise in mass spectrometry (MS)-based proteomics and multiomics, immunology, signaling and epigenetic regulation of inflammation, proteogenomics, cancer biology, molecular and cellular biology. His pioneering work on introducing mass tags with stable isotopes, termed amino acid-coded mass tagging (AACT), a.k.a. SILAC, as a new strategy for proteomic research, was recognized in 1999 with the prestigious Presidential Early Career Award for Scientists and Engineers, the highest award in US to the scientists at their early careers. He is also the inventor of an array of functional proteomic approaches for the discovery of disease markers and new drug targets, including Chromatin-activity-based Chemoproteomics (ChaC) and ChaC-based multi-omics. Dr. Chen has a long-standing interest in understanding the molecular pathways and mechanisms underlying chronic inflammation-associated diseases such as cancer, sepsis, Alzheimer’s disease, diabetes, and COVID-19. In these research areas he has authored and co-authored more than 160 papers including some in high impact journals such as Nature, Science, Cell, Nature Immunology, Molecular Cell, Immunity, Cancer Discovery, Nature Cancer, Cell Reports, Science Advances, Nature Communications, Cell Chemical Biology, iScience, etc. He also holds five patents for his technology innovations and a provisional patent application for ‘New Therapeutics for COVID-19’. His H-index is at 60 with 32,440 citations.

Jordan Currie

Coming Soon!

Lars Plate

Coming Soon!

Andy Tao

Prof. W. Andy Tao's group focuses on new developments in proteome analyses using systems biology approaches. He received his mass spectrometry training through his dissertation work on gas-phase chiral analysis in the Aston Lab at Purdue University, headed by Dr. R. Graham Cooks. After receiving his Ph.D. in December 2001, he became a Damon Runyon Postdoctoral Fellow in the Institute for Systems Biology at Seattle, under the supervision of Drs. Leroy Hood and Ruedi Aebersold. He started his own research group in the Department of Biochemistry at Purdue University in 2005, and currently is Professor in ranking. He also has joined appointments in the Department of Chemistry, Department of Medicinal Chemistry & Molecular Pharmacology at Purdue University.

Jennifer Van Eyk

Dr. Van Eyk is a Professor of Medicine at Cedars-Sinai Medical Center, Director of the Basic Science Research in the Barbra Streisand Woman’s Hearth Center and Director of the new Advance Clinical Biosystems Institute where she recently moved from Johns Hopkins University. Most recently she has become the co-director of the Cedars Sinai Precision Health, focused on in-hospital and population individualization of health care. Dr. Van Eyk is an international leader in the area of clinical proteomics and her lab has focused the developing technical pipelines for de novo discovery and larger scale quantitative mass spectrometry methods. This includes multiple reaction monitoring (MRM, also known as SRM) and most recently data independent acquisition. Her laboratory is well known for the extreme technical quality of the data generated, rigorous quality control with tight %CV while applying these to key clinical questions. The aim is to maximize throughput and reproducibility in order to move targeted and robust discovery methods into large population healthy continuous assessment and clinical grade assays focusing on brain and cardiovascular diseases.

Che-Fan Huang

Coming Soon!

Andy Y. Qi

Coming Soon!

Devin Schweppe

Coming Soon!

Rebekah Gundry

Coming Soon!

Aaron Gajadhar

Coming Soon!

Asim Siddiqui

Coming Soon!

Birgit Schilling

Dr. Schilling is a Professor and the Director of the Mass Spectrometry Core at the Buck Institute for Research on Aging in California, and she is also an Adjunct Professor at the University of Southern California (USC). The Schilling lab develops and implements advanced innovative protein analytical technologies (including quantitative proteomics, posttranslational modifications, protein dynamics and biomarker discovery) to advance basic biology and biomedical research related to aging research. Several research projects include investigation of protein phosphorylation, acylation, and other posttranslational modifications, as well as differential expression of proteins during disease and aging processes. We are particularly interested in deciphering underlying mechanisms of senescence during aging, and we have developed MS methodologies to quantitatively analyze protein secretomes, secreted exosomes and to perform accurate quantitative protein expression workflows. The Schilling lab has adopted several novel proteomic technologies with comprehensive and extremely sensitive quantification capabilities, and these are particularly applicable for the proposed project. We are using proteomic data-independent acquisitions (DIA), or SWATH which allows us to accurately determine changes in relative protein expression level between multiple different conditions.

Robert Kennedy

Robert Kennedy is the Hobart H. Willard Distinguished University Professor of Chemistry and Professor of Pharmacology at the University of Michigan. He earned a PhD at University of North Carolina in 1988 where his work focused on using open tubular LC to analyze single cells. After a post-doc in neuroscience he started his own research program at University of Florida in 1991 before moving to University of Michigan as the Hobart H. Willard Professor of Chemistry in 2002. His research has combined his interest in biology with chemical analysis and separations. A theme of his group has been development of new chemical analysis tools that can be used at the nanoscale for several applications including screening of drugs, engineering enzymes, monitoring neurotransmitters in the brain, and studying the secretion of insulin and other hormones. His work has been recognized by several awards including the American Chemical Society Award in Chromatography, the Ralph Adams Award in Bioanalytical Chemistry, and NIH MERIT awards. He has held several service posts including Chair of the Chemistry Department at University of Michigan and is presently Associate Editor of Analytical Chemistry and ACS Measurement Science Au.

Michael Gilbert

Coming Soon!

Bethany Taylor

Coming Soon!

Ewa Bomba-Warczak

Dr. Ewa Bomba-Warczak is a neuroscientist and mitochondrial biologist investigating the lifelong fidelity of mitochondria in mammalian brains. She obtained her B.S. in Biological Sciences from the University of Illinois at Chicago, and her doctorate in Neuroscience from University of Wisconsin - Madison under the tutelage of Dr. Edwin Chapman, an HHMI Investigator. As an NINDS MOSAIC K99/R00 Scholar and ASCB Fellow in the lab of Dr. Jeffrey Savas at Northwestern University, she focuses on the application of in vivo whole rodent metabolic stable isotope pulse-chase labeling combined with proteomic mass spectrometry (MS)-based analysis to investigate the mechanisms governing the longevity of mitochondrial proteins and mtDNA.

Josh Coon

Hailing from a small town in central Michigan, Coon escaped from the cold to earn a Ph.D. at the University of Florida. He went on to conduct his postdoctoral studies with Don Hunt at the University of Virginia. During that time he, along with Hunt and John Syka, co-invented electron transfer dissociation. In 2005 he joined the faculty at Wisconsin to start his own program. Coon’s research group aims to advance mass spectrometer technology to make proteome analysis faster and more accessible. Coon’s research in these areas has been recognized by several awards including the Biemann Medal from the American Society for Mass Spectrometry and the Ken Standing Award from the University of Manitoba. He is the Director of the NIGMS funded National Center for Quantitative Biology of Complex Systems.

Emily Chapman

Coming Soon!

Xiaojing Sui

Coming Soon!

Carlito Lebrilla

Dr. Carlito B. Lebrilla is a Distinguished Professor at the University of California, Davis in the Department of Chemistry and Biochemistry and Molecular Medicine in the School of Medicine. He received his BS degree from the University of California, Irvine and Ph.D. from the University of California, Berkeley. He was an Alexander von Humboldt Fellow and a NSF-NATO Fellow at the Technical University in Berlin. He returned to the UC Irvine as a President’s Fellow and has been at UC Davis. He has served as Chair of the Chemistry Department. His research is in Analytical Chemistry focused on mass spectrometry with applications to clinical glycomics and biofunctional food. He has over 450 peer-reviewed publications with an H-index of 95. He has co-founded several start-ups in the areas of bioactive foods and disease biomarkers. He has been awarded the Field and Franklin Medal for outstanding contributions to mass spectrometry, MCP Lectureship in Glycobiology, UCD Outstanding Researcher Award and UCD Innovator Award. He is also co-editor of Mass Spectrometry Reviews and has been on the editorial board of Molecular and Cellular Proteomics, Glycobiology, Mass Spectrometry Reviews, Journal of American Society for Mass Spectrometry, European Mass Spectrometry, and International Journal of Mass Spectrometry.

Chris Anderton

Dr. Chris Anderton is the team leader for the Biogeochemical Transformations team in PNNL’s Environmental Molecular Sciences Division and the Environmental Molecular Sciences Laboratory (EMSL) user program. He has an extensive background in elucidating chemical interactions occurring across all kingdoms of life, including those within soils and the rhizosphere.  Through his graduate endeavors to his recent position, he focuses on the power of multimodal imaging methods to expand the type of information gained from samples. For his graduate work and postdoc at National Institute of Standards and Technology, he used atomic force microscopy, scanning electron microscopy, and secondary ion mass spectrometry to understand the physicochemical properties of biological samples. At PNNL, his focus has been, in part, on expanding the mass spectrometry imaging capability within EMSL—making these valuable tools for analyzing bacteria communities, rhizosphere-related systems, and even human health-related processes. He also focuses on visualizing the key mechanisms that drive interkingdom interactions within soil to understand the key drivers that lead to resiliency in the face of a changing environment.

Dominick Pierre-Jacques

Coming Soon!

Brian DeFelice

Coming Soon!

Andrew Emili

Prof. Andrew Emili is internationally recognized for his research in functional proteomics, interactomics and systems biology. Prof. Emili’s research lab develops innovative technologies to map cellular protein interaction networks on a global-scale, publishing interactome maps of unprecedented quality, scope and resolution. He oversees a multi-disciplinary research program advancing functional proteomics technologies, including methods to profile protein-ligand networks with high resolution in model systems for both basic and translational projects.

Amy Weeks

Amy Weeks is an Assistant Professor of Biochemistry at the University of Wisconsin-Madison. She received her S.B. in Chemistry from the Massachusetts Institute of Technology and earned her Ph.D. in Chemistry at the University of California, Berkeley under the mentorship of Prof. Michelle Chang. She completed postdoctoral studies in the laboratory of Prof. James Wells at the University of California, San Francisco. Her research group is focused on developing technologies for mapping the spatial organization and temporal dynamics of cellular signaling.

Lisa Boatner

Coming Soon!

Martin Golkowski

Coming Soon!

Veronica Anania

Veronica Anania, PhD. is a Senior Principal Scientist and Director of the Biomarker Mass Spectrometry Group within the Department of Translational Medicine at Genentech. Her laboratory utilizes mass spectrometry approaches to enable biomarker hypothesis testing in the context of clinical trials. Her research aims to develop state-of-the-art targeted MS and DIA-MS approaches to enable measurement of pharmacodynamic analytes in a broad range of clinical matrices in order to identify early biomarkers reflective of proof of activity for investigational new drugs. Results from these studies support forward and reverse translation efforts and inform clinical biomarker strategies in key therapeutic areas including inflammatory bowel disease, multiple sclerosis, lupus, fibrosis, and Alzheimer’s Disease.

Nicholas Riley

Nick Riley is a K99 postdoctoral fellow in 2022 Chemistry Nobel Laureate Prof. Carolyn Bertozzi's lab at Stanford University, and he will start as an assistant professor of Chemistry at the University of Washington in summer 2023. He received his B.S. in Chemistry and Psychology from the University of South Carolina with Honors from the South Carolina Honors College and earned his Ph.D. in Chemistry at the University of Wisconsin-Madison under the mentorship of Prof. Joshua Coon. His research centers around developing mass spectrometry-based technologies for studying extracellular and cell surface biology, with a special focus on glycosylation and the glycoproteome

Bing Zhang

Bing Zhang is a Professor of Molecular and Human Genetics at Baylor College of Medicine. His research encompasses the broad areas of bioinformatics, computational proteomics, proteogenomics, and cancer systems biology. During the past decade, he has established an internationally recognized research program in computational cancer proteogenomics, focusing on integrating genomic, epigenomic, transcriptomic, and proteomic data to gain a comprehensive understanding of human cancer. Together with colleagues in the Clinical Proteomic Tumor Analysis Consortium (CPTAC) and the International Cancer Proteogenome Consortium (ICPC), their studies on more than 10 cancer types have demonstrated that integrated proteogenomic analysis provides functional context to interpret genomic abnormalities, and that proteogenomics enables new advances in cancer biology, diagnosis, prognosis, and targeted and immunotherapies. The impact of Bing’s work is reflected in his publications and his inclusion on the Highly Cited Researchers 2022 list from Clarivate, placing his among world’s most influential scholars based on citations. His research group has developed multiple widely used bioinformatics tools. CustomProDB is one of the first computational proteogenomics tools, and its expansion into NeoFlow enables proteogenomics-based neoantigen prioritization. The pathway and network analysis tool WebGestalt has been serving the biology research community for 17 years. The LinkedOmics web application makes multi-omics data from CPTAC and TCGA directly available and useful to the cancer research community. He is a Cancer Prevention and Research Institute of Texas (CPRIT) Scholar, a McNair Medical Institute Scholar, an associate editor of Clinical Proteomics, and a member of the editorial board of Molecular & Cellular Proteomics.

Yu Gao

Dr. Yu Gao obtained his Ph.D. in Chemistry from Scripps Research under the guidance of Dr. Thomas Kodadek. He did his postdoctoral training in proteomics and bioinformatics with Dr. John R Yates III at Scripps Research. The Gao lab at the University of Illinois Chicago was established in Aug 2018, focusing on developing novel methods for highly sensitive and single-cell proteomics. The Gao lab combines novel sample preparation methods, chemical modification, and bioinformatics to resolve complex biosystems at single-cell resolution. The Gao lab collaborates with a wide range of researchers, including statisticians, clinical scientists, chemists, and biologists, to apply highly sensitive proteomics methods in various disease models and cancer diagnostics. The Gao lab embraces diversity, equity, and open science. Build a better world together.

Alexander Ivanov

Dr. Alexander R. Ivanov holds the position of Associate Professor in the Department of Chemistry & Chemical Biology and a Faculty Fellow at the Barnett Institute of Chemical & Biological Analysis at Northeastern University. Alexander and his team are interested in developing separation- and mass spectrometry-based technologies to answer challenging biomedical questions. His current research focuses on the following areas: deep characterization of limited cell populations (down to single cells) for basic biology and personalized medicine applications; characterization of proteoforms and protein interactions; and isolation and molecular characterization of extracellular microvesicles as new tools for diagnostics and therapy development.

Aleksandra Binek

Coming Soon!

Bowen Shen

Coming Soon!

Yonghao Yu

Dr. Yu received his B.S. in Chemistry from Fudan University (Shanghai, China) in 2001, and then his Ph.D. in Chemistry from the University of California, Berkeley in 2006. His doctoral research with Dr. Julie Leary focused on mass spectrometry-based proteomic technologies and chemical biology of novel protein modifications. Dr. Yu completed his postdoctoral training (2007-2011) with Drs. Steven Gygi and John Blenis in the Department of Cell Biology at Harvard Medical School. During his postdoctoral training, Dr. Yu studied the function and regulation of phosphorylation-dependent signaling mechanisms in cell growth control. Dr. Yu began his independent research career in 2012 in the Department of Biochemistry at the University of Texas Southwestern Medical Center, where he was a CPRIT scholar in cancer research and a Virginia Murchison Linthicum Scholar in Medical Research. He was promoted to Associate Professor with tenure in 2017. In 2022, Dr. Yu was recruited to join the Department of Molecular Pharmacology and Therapeutics at Columbia University Irving Medical Center as a full professor. Using a multidisciplinary approach, his lab has contributed significantly to our molecular understanding of novel covalent protein modifications in the human proteome. Dr. Yu is also particularly interested in translating the mechanistic insights into novel therapeutic strategies for the relevant diseases, including cancer, diabetes, and neurodegeneration. Through the years, Dr. Yu has been involved in many teaching and scientific outreach activities. He has also served on many NIH and DoD advisory panels, including as a current member of the NIH Enabling Bioanalytical and Imaging Technologies (EBIT) Study Section.

Martin Wuhr

Martin obtained his PhD in Systems Biology in Tim Mitchison's lab at Harvard. There he studied how the cell division machinery adapts to the drastically changing cell size in early vertebrate embryos. For his Postdoc, Martin joined the laboratories of Steven Gygi, a leader in quantitative proteomics, and Marc Kirschner, who is interested in the description of cellular processes on the systems level. Martin started his laboratory at the Lewis-Sigler Institute at Princeton in 2016. The laboratory advances quantitative proteomics technology and leverages these and other techniques to obtain a systems-level understanding of cellular organization.

Marco Hadisurya

Coming Soon!

Bokai Song

Coming Soon!

Gilbert Omenn

Gilbert Omenn is the Harold T. Shapiro Distinguished University Professor of Computational Medicine & Bioinformatics, Internal Medicine, Human Genetics, and Public Health at the University of Michigan, Ann Arbor. His research is focused on genes and proteins causing cancers and on big data in medicine. He led the global Human Proteome Project for the past decade. He is a co-founder of the 2020 Consortium on Clinical Characterization of Covid-19 using Electronic Health Records (4CE). He previously worked on biochemical genetics of the brain, environmental risks, health promotion/disease prevention for older adults, and science and health policy. He is author of 667 scientific and medical publications and editor of 18 books. He was a Research Associate with Nobel Laureate Christian B. Anfinsen at NIH, a Howard Hughes Medical Institute Investigator at the University of Washington (UW), Dean of Public Health at UW, member of the Fred Hutchinson Cancer Research Center, and CEO of the University of Michigan Health System. He served as a White House Fellow in 1973-74 at the U.S. Atomic Energy Commission, Associate Director of the White House Office of Science & Technology Policy and Office of Management & Budget (1977-81), and President of the American Association for the Advancement of Science (2005-06). He was a member of the National Cancer Advisory Board, the Society of Fellows of the National Center for Minority Health & Health Disparities, and the Scientific Management Review Committee for the NIH. He chaired COSEPUP for the National Academies and the Presidential/Congressional Commission on Risk Assessment & Risk Management mandated by the Clean Air Act of 1990. He served on the boards of Amgen Inc. and Rohm & Haas Company. He currently serves on boards of the Hastings Center for Bioethics, the Center for Public Integrity, the Weizmann Institute of Science, biotech firms, and the Foundation for the NIH. He is an elected member of the National Academy of Medicine, the Association of American Physicians, and the American Academy of Arts and Sciences and a fellow of the American College of Physicians, the National Academy for Social Insurance, and the AAAS. He received the John W. Gardner Legacy of Leadership Award from the White House Fellows, Walsh McDermott Medal from the National Academy of Medicine, and David E. Rogers Award from the Association of American Medical Colleges. He holds the BA from Princeton, MD from Harvard, and PhD in Genetics from the University of Washington. He is married to Martha Darling, White House Fellow ’77-’78. He has three children and eight grandchildren. He is an active musician and tennis player. He was among the founders and long-serving Council members of HUPO and the US HUPO and one of the early presidents of US HUPO. The US HUPO Computational Proteomics Award bears his name.